The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study

Andre LamyCADENCE Research Group, Hamilton Health Sciences Corporation, Hamilton, Ontario, Canada, Department of Surgery, Department of Clinical Epidemiology and Biostatistics, and Population Health Research Institute, McMaster University Hamilton, Ontario, CanadaCorrespondence[email protected]

Xiaoyin WangCADENCE Research Group, Hamilton Health Sciences Corporation, Hamilton, Ontario, Canada, and Population Health Research Institute, McMaster University Hamilton, Ontario, Canada

Peggy GaoPopulation Health Research Institute, McMaster University Hamilton, Ontario, Canada

Wesley TongCADENCE Research Group, Hamilton Health Sciences Corporation, Hamilton, Ontario, Canada, and Population Health Research Institute, McMaster University Hamilton, Ontario, Canada

Amiram GafniDepartment of Clinical Epidemiology and Biostatistics, Population Health Research Institute, McMaster University, and Center for Health Economics and Policy Analysis, McMaster University Hamilton, Ontario, Canada

Antonio DansSection of Adult Medicine, College of Medicine, University of the Philippines ManilaPhilippines

Alvaro AvezumResearch Division, Instituto Dante Pazzanese de Cardiologia Sao Paulo, Brazil

Rafael FerreiraPraceta do Comercio Alfragide, Amadora, Portugal

James YoungKaufman Center for Heart Failure, Cleveland Clinic Cleveland, OH, USA

Salim YusufDepartment of Clinical Epidemiology and Biostatistics, Population Health Research Institute, and Department of Cardiology, McMaster University Hamilton, Ontario, Canada

Koon TeoDepartment of Clinical Epidemiology and Biostatistics, Population Health Research Institute, and Department of Cardiology, McMaster University Hamilton, Ontario, Canada

& on behalf of the ONTARGET Investigators show all

The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study

Table 1. Summary of the ONTARGET results.

Table 2. Frequency of all hospitalizations and procedures.

Table 3. Average costs per patient (with 95% CI) for all ONTARGET patients.

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study

Figures & data

Table 1. Summary of the ONTARGET results.

Table 2. Frequency of all hospitalizations and procedures.

Table 3. Average costs per patient (with 95% CI) for all ONTARGET patients.

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date